← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrosoureas
uramustine
L01AD08
Forms & Strengths
- Uramustine capsules: 1 mg
Adult Dosing
- Palliative treatment of lymphomas: 0.15 to 0.4 mg/kg per course, administered as divided doses over several days
- Repeat courses typically withheld until hematologic recovery occurs (usually 3 to 4 weeks)
Pediatric Dosing
- Safety and efficacy in pediatric patients not established; use generally avoided or restricted to specialized protocols
Indications
- Palliative management of chronic lymphocytic leukemia
- Malignant lymphomas including Hodgkin disease and non-Hodgkin lymphomas
- Mycosis fungoides
Mechanism of Action
- Bifunctional alkylating agent (nitrogen mustard derivative)
- Forms covalent bonds with DNA through cross-linking of strands, inhibiting DNA replication and RNA transcription
Contraindications
- Hypersensitivity to uramustine or other nitrogen mustards
- Severe bone marrow depression and preexisting cytopenias
- Severe hepatic or renal impairment
- Pregnancy and lactation
Adverse Reactions
- Severe myelosuppression (leukopenia, thrombocytopenia, anemia)
- Nausea, vomiting, and anorexia
- Alopecia
- Amenorrhea, azoospermia, and gonadal suppression
- Secondary malignancies with prolonged use
Drug Interactions
- Additive bone marrow suppression when combined with other myelosuppressive agents or radiation therapy
- Live virus vaccines: risk of severe systemic infections due to immunosuppression
- Immunosuppressants: increased risk of severe infection and secondary malignancies
Curated Content: Needs Vetting Before Put to Clinical Use